Endocrine-resistance breast cancers

Moving the Needle in ER-Positive/HER2-Negative Metastatic Breast Cancer: Exploring SERD Strategie...Подробнее

Moving the Needle in ER-Positive/HER2-Negative Metastatic Breast Cancer: Exploring SERD Strategie...

The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 sympos...Подробнее

The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 sympos...

Prognostic and predictive potential of CXCL11 in endocrine resistance in breast cancerПодробнее

Prognostic and predictive potential of CXCL11 in endocrine resistance in breast cancer

JCO Article Insights: Adoption of Capivasertib in Metastatic Hormone Receptor–Positive, HER2-Nega...Подробнее

JCO Article Insights: Adoption of Capivasertib in Metastatic Hormone Receptor–Positive, HER2-Nega...

BBCC 2024 - Hall A - Day 1 - The not so Easy Luminal Breast CancerПодробнее

BBCC 2024 - Hall A - Day 1 - The not so Easy Luminal Breast Cancer

INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast CancerПодробнее

INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer

Moving the Needle in ER-Positive/HER2-Negative Metastatic Breast Cancer: Exploring SERD StrategiesПодробнее

Moving the Needle in ER-Positive/HER2-Negative Metastatic Breast Cancer: Exploring SERD Strategies

The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposi...Подробнее

The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposi...

Rethinking Breast Cancer: Optimal Trial Design and Exploring Novel ModalitiesПодробнее

Rethinking Breast Cancer: Optimal Trial Design and Exploring Novel Modalities

APOBEC3 mutational signatures and therapy resistance in breast cancerПодробнее

APOBEC3 mutational signatures and therapy resistance in breast cancer

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...Подробнее

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...

First-Line Endocrine-Based Therapy for Patients with HR+, HER2-Negative Metastatic Breast CancerПодробнее

First-Line Endocrine-Based Therapy for Patients with HR+, HER2-Negative Metastatic Breast Cancer

Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway AbnormalitiesПодробнее

Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities

"In Pursuit of Precision: Breast Surgery Research at The University of Washington"Подробнее

'In Pursuit of Precision: Breast Surgery Research at The University of Washington'

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring...Подробнее

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring...

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerПодробнее

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positiv...Подробнее

Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positiv...

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring...Подробнее

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring...

Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breas...Подробнее

Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breas...

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...Подробнее

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...